A detailed history of Jane Street Group, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 161,193 shares of ZNTL stock, worth $483,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares
161,193
Previous 172,989 6.82%
Holding current value
$483,579
Previous $707,000 16.41%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.9 - $4.57 $34,208 - $53,907
-11,796 Reduced 6.82%
161,193 $591,000
Q2 2024

Aug 14, 2024

BUY
$4.09 - $16.13 $199,191 - $785,563
48,702 Added 39.19%
172,989 $707,000
Q1 2024

May 15, 2024

BUY
$10.83 - $16.49 $847,750 - $1.29 Million
78,278 Added 170.14%
124,287 $1.96 Million
Q4 2023

Feb 14, 2024

BUY
$9.84 - $20.13 $66,242 - $135,515
6,732 Added 17.14%
46,009 $697,000
Q3 2023

Nov 14, 2023

BUY
$19.63 - $28.29 $291,642 - $420,304
14,857 Added 60.84%
39,277 $787,000
Q2 2023

Aug 14, 2023

BUY
$17.41 - $30.05 $76,569 - $132,159
4,398 Added 21.97%
24,420 $688,000
Q1 2023

May 15, 2023

BUY
$16.14 - $24.94 $157,897 - $243,988
9,783 Added 95.55%
20,022 $344,000
Q4 2022

Feb 14, 2023

SELL
$18.07 - $25.6 $581,257 - $823,475
-32,167 Reduced 75.85%
10,239 $206,000
Q3 2022

Nov 14, 2022

BUY
$20.23 - $31.73 $666,295 - $1.05 Million
32,936 Added 347.79%
42,406 $919,000
Q2 2022

Aug 16, 2022

BUY
$17.91 - $52.25 $74,881 - $218,457
4,181 Added 79.05%
9,470 $266,000
Q4 2021

Feb 15, 2022

BUY
$66.92 - $84.79 $353,939 - $448,454
5,289 New
5,289 $445,000
Q1 2021

May 18, 2021

SELL
$35.69 - $52.72 $673,684 - $995,142
-18,876 Closed
0 $0
Q4 2020

Feb 17, 2021

BUY
$31.71 - $57.97 $598,557 - $1.09 Million
18,876 New
18,876 $980,000
Q3 2020

Nov 17, 2020

SELL
$27.03 - $47.97 $351,227 - $623,322
-12,994 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$23.2 - $54.8 $301,460 - $712,071
12,994 New
12,994 $624,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.